Cybin Rallies After Steve Cohen’s Point 72 Disclosed 8.1% Equity Purchase
Renowned hedge fund manager and Wall Street mogul Steve Cohen is showing his confidence in the psychedelic sector. Cohen’s hedge
Read more
Psychedelics
Filament Health To Merge With SPAC To Obtain Nasdaq Listing
Filament Health (NEO: FH) is claiming that shareholders are about to receive US$0.85 per share in value following an agreement
Read more
Snowfall at the White House: Cocaine Found on White House Grounds Sparks Evacuation, Secret Service Investigation
The White House and its surroundings were temporarily evacuated on Sunday following the discovery of an unknown substance on the
Read more
FDA Releases Guidance for Psychedelic Drug Trials With Possibility of Removing Schedule I Classification
The U.S. Food and Drug Administration (FDA) has released a groundbreaking draft guidance to provide crucial insights for researchers exploring
Read more
Psyched Wellness Attracts Major Investment
Jeffrey Stevens, CEO & Director of Psyched Wellness (CSE: PSYC) joins us in today’s episode of the Daily Dive. Jeff
Read more
Quebec Makes History As First Province in Canada to Cover Psilocybin-Assisted Psychotherapy
Last week, Quebec became the first governing medical body in Canada to publicly fund medical psilocybin-assisted psychotherapy, with advocates hoping
Read more
Mind Medicine Prices $30 Million Offering At 30% Discount To Market
Mind Medicine (NEO: MMED) has elected to destroy shareholder value in a major way this morning, pricing yet another financing
Read more
Bright Minds Begins Phase 1 Clinical Trials Focused On Treating Dravet Syndrome
Phase 1 trials are officially underway for Bright Minds Biosciences (CSE: DRUG) and their lead product, referred to as BMB-101.
Read more
Mindmed Completes 15-To-1 Reverse Split To Maintain Nasdaq Compliance
Mind Medicine (NEO: MMED) might be slightly more volatile over the next few sessions. The psychedelic firm late on Friday
Read more
Mind Medicine Begins Phase 2B Study On Treating Generalized Anxiety Disorder With LSD Variant
Mind Medicine (NEO: MMED) has officially seen patient trials under a Phase 2b study get underway as it looks to
Read more